Eli Lilly (LLY) Common Equity (2009 - 2026)

Eli Lilly (LLY) has reported Common Equity for 18 consecutive years, with $31.2 billion the latest figure, recorded in Q1 2026.

• Common Equity for Q1 2026 came in at $31.2 billion, up 106.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $31.2 billion (up 106.61% YoY), and the FY2025 annual result was $26.5 billion, up 1210.25% from the prior year.
• Common Equity was $31.2 billion for Q1 2026 at Eli Lilly, up from $26.5 billion in the prior quarter.
• Over five years, Common Equity peaked at $31.2 billion in Q1 2026 and troughed at -$3.8 billion in Q4 2022.
• Average Common Equity over 5 years is $4.6 billion, with a median of -$2.2 billion recorded in 2025.
• The widest YoY moves for Common Equity: up 46277.37% in 2025, down 6607.65% in 2025.
• Over 5 years, Common Equity stood at -$3.8 billion in 2022, then rose by 29.86% to -$2.7 billion in 2023, then grew by 11.38% to -$2.4 billion in 2024, then jumped by 1210.25% to $26.5 billion in 2025, then gained by 17.57% to $31.2 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $31.2 billion in Q1 2026, $26.5 billion in Q4 2025, and $23.8 billion in Q3 2025.